These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36894038)

  • 1. Reproductive findings in male animals exposed to selective survival of motor neuron 2 (SMN2) gene splicing-modifying agents.
    Mueller L; Barrow P; Jacobsen B; Ebeling M; Weinbauer G
    Reprod Toxicol; 2023 Jun; 118():108360. PubMed ID: 36894038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs.
    Poirier A; Weetall M; Heinig K; Bucheli F; Schoenlein K; Alsenz J; Bassett S; Ullah M; Senn C; Ratni H; Naryshkin N; Paushkin S; Mueller L
    Pharmacol Res Perspect; 2018 Dec; 6(6):e00447. PubMed ID: 30519476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risdiplam: an investigational survival motor neuron 2 (SMN2) splicing modifier for spinal muscular atrophy (SMA).
    Markati T; Fisher G; Ramdas S; Servais L
    Expert Opin Investig Drugs; 2022 May; 31(5):451-461. PubMed ID: 35316106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a CNS penetrant small molecule SMN2 splicing modulator with improved tolerability for spinal muscular atrophy.
    Ando S; Suzuki S; Okubo S; Ohuchi K; Takahashi K; Nakamura S; Shimazawa M; Fuji K; Hara H
    Sci Rep; 2020 Oct; 10(1):17472. PubMed ID: 33060681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The oral splicing modifier RG7800 increases full length survival of motor neuron 2 mRNA and survival of motor neuron protein: Results from trials in healthy adults and patients with spinal muscular atrophy.
    Kletzl H; Marquet A; Günther A; Tang W; Heuberger J; Groeneveld GJ; Birkhoff W; Mercuri E; Lochmüller H; Wood C; Fischer D; Gerlach I; Heinig K; Bugawan T; Dziadek S; Kinch R; Czech C; Khwaja O
    Neuromuscul Disord; 2019 Jan; 29(1):21-29. PubMed ID: 30553700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 ( SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA).
    Ratni H; Ebeling M; Baird J; Bendels S; Bylund J; Chen KS; Denk N; Feng Z; Green L; Guerard M; Jablonski P; Jacobsen B; Khwaja O; Kletzl H; Ko CP; Kustermann S; Marquet A; Metzger F; Mueller B; Naryshkin NA; Paushkin SV; Pinard E; Poirier A; Reutlinger M; Weetall M; Zeller A; Zhao X; Mueller L
    J Med Chem; 2018 Aug; 61(15):6501-6517. PubMed ID: 30044619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier.
    Sturm S; Günther A; Jaber B; Jordan P; Al Kotbi N; Parkar N; Cleary Y; Frances N; Bergauer T; Heinig K; Kletzl H; Marquet A; Ratni H; Poirier A; Müller L; Czech C; Khwaja O
    Br J Clin Pharmacol; 2019 Jan; 85(1):181-193. PubMed ID: 30302786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risdiplam: A Review in Spinal Muscular Atrophy.
    Paik J
    CNS Drugs; 2022 Apr; 36(4):401-410. PubMed ID: 35284988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addressing Today's Absorption, Distribution, Metabolism, and Excretion (ADME) Challenges in the Translation of In Vitro ADME Characteristics to Humans: A Case Study of the
    Fowler S; Brink A; Cleary Y; Günther A; Heinig K; Husser C; Kletzl H; Kratochwil N; Mueller L; Savage M; Stillhart C; Tuerck D; Ullah M; Umehara K; Poirier A
    Drug Metab Dispos; 2022 Jan; 50(1):65-75. PubMed ID: 34620695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells.
    Pagliarini V; Guerra M; Di Rosa V; Compagnucci C; Sette C
    J Neurochem; 2020 Apr; 153(2):264-275. PubMed ID: 31811660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific Correction of Alternative Survival Motor Neuron 2 Splicing by Small Molecules: Discovery of a Potential Novel Medicine To Treat Spinal Muscular Atrophy.
    Ratni H; Karp GM; Weetall M; Naryshkin NA; Paushkin SV; Chen KS; McCarthy KD; Qi H; Turpoff A; Woll MG; Zhang X; Zhang N; Yang T; Dakka A; Vazirani P; Zhao X; Pinard E; Green L; David-Pierson P; Tuerck D; Poirier A; Muster W; Kirchner S; Mueller L; Gerlach I; Metzger F
    J Med Chem; 2016 Jul; 59(13):6086-100. PubMed ID: 27299419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Male Reproduction in Spinal Muscular Atrophy (SMA) and the Potential Impact of Oral Survival of Motor Neuron 2 (SMN2) Pre-mRNA Splicing Modifiers.
    Bar-Chama N; Elsheikh B; Hewamadduma C; Guittari CJ; Gorni K; Mueller L
    Neurol Ther; 2024 Aug; 13(4):933-947. PubMed ID: 38750391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risdiplam: First Approval.
    Dhillon S
    Drugs; 2020 Nov; 80(17):1853-1858. PubMed ID: 33044711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Securinine enhances SMN2 exon 7 inclusion in spinal muscular atrophy cells.
    Chen YC; Chang JG; Liu TY; Jong YJ; Cheng WL; Yuo CY
    Biomed Pharmacother; 2017 Apr; 88():708-714. PubMed ID: 28152480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JEWELFISH: 24-month results from an open-label study in non-treatment-naïve patients with SMA receiving treatment with risdiplam.
    Chiriboga CA; Bruno C; Duong T; Fischer D; Mercuri E; Kirschner J; Kostera-Pruszczyk A; Jaber B; Gorni K; Kletzl H; Carruthers I; Martin C; Scalco RS; Fontoura P; Muntoni F;
    J Neurol; 2024 Aug; 271(8):4871-4884. PubMed ID: 38733387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial.
    Masson R; Mazurkiewicz-Bełdzińska M; Rose K; Servais L; Xiong H; Zanoteli E; Baranello G; Bruno C; Day JW; Deconinck N; Klein A; Mercuri E; Vlodavets D; Wang Y; Dodman A; El-Khairi M; Gorni K; Jaber B; Kletzl H; Gaki E; Fontoura P; Darras BT;
    Lancet Neurol; 2022 Dec; 21(12):1110-1119. PubMed ID: 36244364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recognition of single-stranded nucleic acids by small-molecule splicing modulators.
    Tang Z; Akhter S; Ramprasad A; Wang X; Reibarkh M; Wang J; Aryal S; Thota SS; Zhao J; Douglas JT; Gao P; Holmstrom ED; Miao Y; Wang J
    Nucleic Acids Res; 2021 Aug; 49(14):7870-7883. PubMed ID: 34283224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-(N-ethyl-N-isopropyl)-amiloride enhances SMN2 exon 7 inclusion and protein expression in spinal muscular atrophy cells.
    Yuo CY; Lin HH; Chang YS; Yang WK; Chang JG
    Ann Neurol; 2008 Jan; 63(1):26-34. PubMed ID: 17924536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A role for SMN exon 7 splicing in the selective vulnerability of motor neurons in spinal muscular atrophy.
    Ruggiu M; McGovern VL; Lotti F; Saieva L; Li DK; Kariya S; Monani UR; Burghes AH; Pellizzoni L
    Mol Cell Biol; 2012 Jan; 32(1):126-38. PubMed ID: 22037760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SMN protein is required throughout life to prevent spinal muscular atrophy disease progression.
    Zhao X; Feng Z; Risher N; Mollin A; Sheedy J; Ling KKY; Narasimhan J; Dakka A; Baird JD; Ratni H; Lutz C; Chen KS; Naryshkin NA; Ko CP; Welch E; Metzger F; Weetall M
    Hum Mol Genet; 2021 Dec; 31(1):82-96. PubMed ID: 34368854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.